🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

2,153 results for “Ou” Clear

  1. Ara-C Group

    The First People's Hospital of Lianyungang

    Acute Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  2. Arm 1： Standard Synchronous Group

    The First People's Hospital of Lianyungang

    Advanced Non-Small Cell Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  3. Arm1

    Hospital Authority, Hong Kong

    Oral Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  4. Asciminib, ASCIMINIB HYDROCHLORIDE

    Novartis Pharmaceuticals

    Philadelphia positive Chronic Myeloid leukemia in Chronic Phase with newly diagnosed and resistant/intolerant to previous TKIs, with or without the T315I mutation

    phase 2 small molecule active

    1 trial

  5. Aspirin

    Cardiff Oncology

    Venous Leg Ulcer

    phase 2 small molecule terminated

    1 trial

  6. Assets Getting To Outcomes

    BRIGHT MINDS BIOSCIENCES INC.

    Substance Abuse

    phase 2 other completed

    1 trial

  7. Autologous (self) mononuclear cells derived from umbilical cord blood

    Regeneron Ireland Designated Activity Company (DAC)

    Hypoplastic Left Heart Syndrome

    phase 2 mab active

    1 trial

  8. Autologous BCMA-targeting CAR T cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Multiple Myeloma in Relapse

    phase 2 mab active

    1 trial

  9. Autologous Bone Marrow Mononuclear Cells

    Lxo Ireland Designated Activity Company

    Peripheral Vascular Diseases

    phase 2 other completed

    1 trial

  10. Autologous CD5 CAR T-cells

    The First People's Hospital of Lianyungang

    T-Cell Acute Lymphocytic Leukemia

    phase 2 small molecule active

    1 trial

  11. Autologous CD5 CAR T-cells

    Universal Integrated

    T-Cell Acute Lymphocytic Leukemia

    phase 2 small molecule active

    1 trial

  12. Autologous CD7 CAR T-cell

    Universal Integrated

    T-cell Acute Lymphoblastic Leukemia

    phase 2 small molecule active

    1 trial

  13. Autologous Fat Transfer

    United Therapeutics Europe Ltd

    Wound

    phase 2 other completed

    1 trial

  14. Autologous Room Temperature stored Platelet transfusion

    United Therapeutics Europe Ltd

    Reversal of Platelet Aggregation Inhibitors

    phase 2 mab active

    1 trial

  15. Autologous Skin Fibroblasts

    United Therapeutics Europe Ltd

    Amputation

    phase 2 mab active

    1 trial

  16. Autologous Tumor Infiltrating Lymphocytes MDA-TIL

    Iovance Biotherapeutics B.V.

    Malignant Solid Neoplasm

    phase 2 mab terminated

    1 trial

  17. Autologous Volar Fibroblast Injection into the Terminal Limb of Amputees

    United Therapeutics Europe Ltd

    Amputation

    phase 2 other active

    1 trial

  18. Autologous adipose derived mesenchymal stem cells

    Lxo Ireland Designated Activity Company

    Critical Limb Ischemia (CLI)

    phase 2 small molecule completed

    1 trial

  19. Autologous bone marrow mononuclear cell transplantation

    EuroGen Pharmaceuticals Ltd

    Spinal Cord Injury

    phase 2 mab terminated

    1 trial

  20. Autologous hematopoietic stem cell infusion

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Prolonged Cytopenia Following CAR-T Therapy

    phase 2 mab active

    1 trial

  21. Autologous mesenchymal stem cells from adipose tissue.

    Lxo Ireland Designated Activity Company

    Autoimmune Diseases

    phase 2 other completed

    1 trial

  22. Avapritinib, azacitidine, Venetoclax

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    AML (Acute Myelogenous Leukemia)

    phase 2 small molecule active

    1 trial

  23. Avastin 25 mg/ml concentrate for solution for infusion., ACIDO VALPROICO E SODIO VALPROATO ratiopharm 500 mg compresse a rilascio prolungato, Oxaliplatino Accord 5 mg/ml concentrato per soluzione per infusione, FLUOROURACILE PFIZER 50 mg/mL, solution à diluer pour perfusion, Capecitabina Glenmark 150 mg comprimidos recubiertos con película EFG

    Fondazione Telethon ETS

    Patients with ras-mutated metastatIc colorectal cancer

    phase 2 small molecule active

    1 trial

  24. Avastin 25 mg/ml concentrate for solution for infusion., Vectibix 20 mg/ml concentrate for solution for infusion, Folinato Cálcico Hikma, 10 mg/ml solución inyectable y para perfusión EFG, Oxaliplatino Kabi 5 mg/ml concentrado para solución para perfusión EFG, Erbitux 5 mg/mL solution for infusion, Irinotecan Hydrochloride Trihydrate Fair-Med Healthcare 20 mg/ml concentrate for solution for infusion, Fluorouracilo Accord 50 mg/ml solución inyectable o para perfusión EFG

    Disc Medicine

    Colorectal cancer and metastatic disease limited to the liver with bad prognosis.

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources